Lucanthone
- Generic Name
- Lucanthone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N2OS
- CAS Number
- 479-50-5
- Unique Ingredient Identifier
- FC6D57000M
- Background
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
- Indication
Intended for use as a radiation sensitizer in the treatment of brain cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Phase 2
Withdrawn
- Conditions
- Brain MetastasesNon-small Cell Lung Cancer
- Interventions
- Other: PlaceboDrug: Lucanthone
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT02014545
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
Phase 2
Terminated
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 18
- Registration Number
- NCT01587144
- Locations
- 🇮🇳
Bhagwan Mahaveer Cancer Hospital & Reseach Centre, Jaipur, Rajasthan, India
🇮🇳Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
🇮🇳Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath